Date | Price Target | Rating | Analyst |
---|---|---|---|
1/31/2022 | $15.00 | Buy | HC Wainwright & Co. |
10/19/2021 | $16.00 | Hold → Buy | Maxim Group |
SC 13G/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)
SC 13G/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)
SC 13D/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)
S-1 - Indaptus Therapeutics, Inc. (0001857044) (Filer)
D - Indaptus Therapeutics, Inc. (0001857044) (Filer)
S-8 - Indaptus Therapeutics, Inc. (0001857044) (Filer)
4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
HC Wainwright & Co. resumed coverage of Indaptus Therapeutics with a rating of Buy and set a new price target of $15.00
Maxim Group upgraded Indaptus Therapeutics from Hold to Buy and set a new price target of $16.00
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, provides an update regarding key clinical advancements. The independent Safety Review Committee overseeing the Company's Phase 1 clinical trial convened in August to review the safety data at the higher Decoy20 dose with single dose administration and the safety data at the lower Decoy20 dose with weekly administration. The encouraging data has led to the decision to: Continue dosing additional patients at the lower Decoy20 dose on a weekly scheduleInitiate dos
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel. Presentation Date:September 9, 2024Time:Available on-demand starting at 7:00 AM Eastern TimeWebcast Link:https://journey.ct.events/view/3a63636e-c1c2-4558-8c2e-97028c46cb66 A live webcast of the presentation can be accessed on the investor relations section of the Indaptus website. A replay of the webcast will be archived and available following the e
NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update. Jeffrey Meckler, Indaptus Therapeutics' Chief Executive Officer, commented, "During the second quarter we had multiple opportunities to share our findings regarding our Phase 1 clinical trial to date, and to demonstrate the unique approach that our Decoy platform offers. These included impactful conferences such as the American Association for Cancer Res
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, is pleased to announce the launch of a new social media initiative to provide education and updates about the company. Recognizing the importance of engaging with all stakeholders, Indaptus will generate content on a variety of digital platforms, including X (formerly known as Twitter) and LinkedIn. Indaptus Therapeutics emerges from over a century of groundbreaking advancements in immunotherapy and has built an approach that is designed to stimulate a broad acting effect on the immune sy
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. "We continue to be encouraged by early results from our first cohort of patients in the INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors. As we recently reported and presented at the Society for Immunology in Cancer (SITC) conference, all four first cohort patients have maintained stable disease since receiving their single dose and presented evidence of immune activation, along with short-lived adverse events consistent with Decoy20's mech
NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. "We have recently announced the completion of the first cohort of patients in our INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors and receipt of authorization from the Safety Review Committee to advance into the second cohort. As previously announced, we are pleased to observe evidence of immune activation, along with short-lived adverse events consistent with Decoy20's mechanism of action," said Jeffrey Meckler, Chief Executive Officer of Indapt
Company Remains On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Q4 2022 NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), today announces financial results for the third quarter ended September 30, 2022 and provides a corporate update. "We continue to diligently prepare for the launch of our Phase 1 trial of Decoy20 for the treatment of solid tumors, while carefully managing our expenses," said Jeffrey Meckler, chief executive officer of Indaptus. "Once we have finalized the initiation process with our trial sites we will be prepared to speak more openly about progress, including tr
U.S. Food and Drug Administration (FDA) Cleared Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in 2022 NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), today announces financial results for the second quarter ended June 30, 2022 and provides a corporate update. "We made substantial progress throughout the second quarter, highlighted by the FDA clearance of our IND application for systemically administered Decoy20. This important regulatory milestone keeps us on track to initiate our first in human clinical trial this year," said
Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half of 2022 NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), today announces financial results for the first quarter ended March 31, 2022 and provides a corporate update. "We are delighted to report the submission of our Investigational New Drug (IND) application for systemically administered Decoy20. The timing of this submission keeps us on track to initiate our first in human clinical trial this year and we look forward to working with the FDA as
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $12 price target.
Gainers Venus Concept (NASDAQ:VERO) shares increased by 135.2% to $1.38 during Friday's pre-market session. The market value of their outstanding shares is at $8.7 million. Adlai Nortye (NASDAQ:ANL) shares moved upwards by 56.64% to $6.72. The market value of their outstanding shares is at $247.9 million. BioCardia (NASDAQ:BCDA) shares moved upwards by 52.57% to $6.66. The market value of their outstanding shares is at $12.1 million. Geron (NASDAQ:GERN) stock rose 22.36% to $4.76. The market value of their outstanding shares is at $2.8 billion. Seelos Therapeutics (NASDAQ:SEEL) stock moved upwards by 14.66% to $1.29. The market value of their outstanding shares is at $3.3 million. Inda